p21WAF1/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cell by Wei, Junxia et al.
RESEARCH ARTICLE Open Access
p21WAF1/CIP1 gene transcriptional activation
exerts cell growth inhibition and enhances
chemosensitivity to cisplatin in lung carcinoma cell
Junxia Wei, Jiang Zhao
2†, Min Long
1†, Yuan Han
1, Xi Wang
1, Fang Lin
1, Jihong Ren
1, Ting He
1, Huizhong Zhang
1*
Abstract
Background: Non-small-cell lung carcinomas (NSCLCs) exhibit poor prognosis and are usually resistant to
conventional chemotherapy. Absence of p21WAF1/CIP1, a cyclin-dependent kinase (cdk) inhibitor, has been linked
to drug resistance in many in vitro cellular models. RNA activation (RNAa) is a transcriptional activation phenomena
guided by double-strand RNA (dsRNA) targeting promoter region of target gene.
Methods: In this study, we explored the effect of up-regulation of p21 gene expression on drug-resistance in A549
non-small-cell lung carcinoma cells by transfecting the dsRNA targeting the promoter region of p21 into A549
cells.
Results: Enhanced p21 expression was observed in A549 cells after transfection of dsRNA, which was correlated
with a significant growth inhibition and enhancement of chemosensitivity to cisplatin in A549 cells in vitro.
Moreover, in vivo experiment showed that saRNA targeting the promoter region of p21 could significantly inhibit
A549 xenograft tumor growth.
Conclusions: These results indicate that p21 plays a role in lung cancer drug-resistance process. In addition, this
study also provides evidence for the usage of saRNA as a therapeutic option for up-regulating lower-expression
genes in lung cancer.
Background
Lung cancer is the most common cause of cancer mor-
tality worldwide. Non-small-cell lung carcinomas
(NSCLCs), which represent around 80% of lung tumors,
exhibit poor prognosis and are usually resistant to con-
ventional chemotherapy. Cisplatin is one of the most
potent anticancer agents, displaying significant clinical
activity against a variety of solid tumors. The most
effective systemic chemotherapy for non-small cell lung
cancer (NSCLC) was cisplatin-based combination treat-
ment. Unfortunately, the outcome of cisplatin therapy
on NSCLC seems to be unsatisfactory. The use of cis-
platin in cancer chemotherapy is limited by acquired or
intrinsic resistance of cells to the drug. The cytotoxicity
of cisplatin is believed mainly due to interaction with
DNA, forming inter-and intra-strand adducts, hindering
both RNA transcription and DNA replication, leading to
cell cycle arrest and apoptosis. Numerous cellular
mechanisms potentially contributing to clinical cisplatin
resistance have been proposed, including changes in cel-
lular drug accumulation, detoxification of the drug, inhi-
bition of apoptosis and repair of the DNA adducts but
the precise mechanisms are still need to be validated. It
has been reported that P21 expression level is involved
in the resistant phenotype of this drug [1-4].
p21WAF1/CIP1 (p21) is a well-characterized cyclin-
dependent kinase (cdk) inhibitor that belongs to the
Cip/Kip family of cdk inhibitors. It mainly inhibits the
activity of cyclin/cdk2 complexes and negatively modu-
lates cell cycle progression [3-6]. Loss or inactivation of
p21 is seen clinically in primary solid tumors and related
with poor prognosis of these tumors [7,8]. Additionally,
there is a growing body of evidence suggesting that
functional loss of p21 can mediate a drug-resistance
phenotype in tumor therapy [9,10].
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activation phenomenon specifically induced by double
small RNA (dsRNA) molecule targeting gene promoter
regions. This phenomenon was termed RNAa and the
dsRNA molecules were designated small activating
RNAs (saRNAs). By targeting gene promoter regions,
saRNAs induce the demethylation of histone, leading to
transcriptional gene activation. It has been demonstrated
that saRNA could inhibit cell proliferation and viability
via up-regulation of p21 and E-cadherin in human blad-
der cancer cells [11-13]. Since saRNAs offer a practical
and cost-effective approach to activate gene expression,
it may be additional method except for ectopic expres-
sion in enhancing expression of targeted genes.
In this study, we explored the effect of up-regulation
of p21 gene expression on drug-resistance in A549 non-
small-cell lung carcinoma cells by transfecting the
saRNA targeting the promoter region of p21 into A549
cells. We observed activation of p21 expression in A549
lung carcinoma cells after transfection of saRNA. The
enhanced p21 expression was correlated with a signifi-
cant growth inhibition and enhancement of chemosensi-
tivity to cisplatin in A549 cells in vitro and vivo. These
results provide evidence of an additional therapeutic
strategy for lung cancer therapy especially for chemore-
sisitance lung carcinomas.
Methods
Design and preparation of dsRNA
saRNA targeting the promoter of p21 at position-322
relative to the transcription start site was termed as
dsP21-322 and designed as previously described [9].
Scramble dsRNA with the following sequence: S, 5’-
UUCUCCGAACGUGUCACGU [dT][dT]-3’;A S ,5 ’-
ACGUGACACGUUCGGAGAA[dT][dT]-3’ was also
synthesized and used as control. Synthetic dsRNAs were
manufactured by Genepharma Inc (Shanghai, China).
Cell culture and transfection
Human lung carcinoma cells (A549) were cultured in Dul-
becco’s modified Eagle’s medium (DMEM, Invitrogen)
supplemented with 10% fetal bovine serum and penicillin
(100 Units/ml)/streptomycin(0.1 mg/ml) in 5% CO2 incu-
bator at 37°C. Cells were seeded into six-well plates with
growth medium at a density of 0.8 × 10
5 cells/well respec-
tively and cultured overnight to (30-50)% confluence prior
to transfection. Cells were then transfected with 100
pmol/well of dsP21-322 or scramble dsRNA, respectively,
using the LipofectamineTM2000 reagent (Invitrogen,
USA) according to the manufacturer’sp r o t o c o l s .
RNA isolation and semi-quantitative RT-PCR
Total RNAs were extracted from dsP21-322, scramble
dsRNA and mock transfected A549 cells by using
TRIzol reagent according to the manufacturer’si n s t r u c -
tions. Complementary DNA (cDNA) was generated
from total RNA by reverse transcription using moloney
murine leukemia virus (M-MLV). PCR amplification of
the cDNA was performed in a reaction mixture with a
final volume of 30 μL containing 2 μLo f4×d N T P s ,
one unit of Taq DNA polymerase, and 10 mmol/L of
each paired primer specific to p21 gene. The primers
used for RT-PCR of p21 were forward primer, 5’-
TTGATTAGCAGCGGAACA-3’ and reverse primer, 5’-
TACAGTCTAGGTGGAGAAACG-3’.
Western blotting
The cells from experiment group and control groups
were harvested and washed with PBS (pH 7.4) twice and
resuspended in lysis buffer (1 mM dithiothreitol, 0.125
mM EDTA, 5% glycerol, 1 mM phenylmethylsulfonyl-
fluoride, 1 μg/mL leupeptin, 1 μg/mL pepstatin, 1 μg/
mL aprotinin, 1% Triton X-100 in 12.5 mM Tris-HCl
buffer, pH 7.0) on ice. The cell extracts were clarified by
centrifugation and the protein concentrations were
determined by using the Bio-Rad protein assay kit (Bio-
Rad, Hercules, CA). Each protein extract (25 μg) was
electrophoresed on a 12% SDS-polyacrylamide gel,
transferred to PVDF membrane in a buffer containing
25 mM Tris-HCl (pH 8.3), 192 mM glycine, 20% (v/v)
methanol, and blocked in 5% (w/v) skimmed milk in
Tris buffered saline-Tween 20 (0.1% by volume, TBST)
for 1 hour at room temperature, and probed with speci-
fic primary antibodies overnight at 4°C. Then primary
antibodies were removed and the blots were extensively
washed with TBST for three times. Blots were then
incubated for an hour at room temperature with the
secondary antibodies (goat anti-rabbit/mouse antibody
coupled to horseradish peroxidase, 1:3000 dilution) in
1% (w/v) skimmed milk dissolved in TBST. Following
removal of the secondary antibody, blots were exten-
sively washed as above for an hour and developed using
the Enhanced Chemiluminescence Kit (NENTM Life
Science Products Inc, Boston, MA). The primary anti-
bodies used in this experiment for western blotting ana-
lysis were anti-p21 (1:100, Santa Cruz) and anti-b-actin
(1:500, Sigma) antibody.
2.5 3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-
2Htetrazolium bromide (MTT) assay
MTT assay was performed to assess the effect of p21
expression on cell proliferation. Transiently transfected
lung carcinoma cells were plated in 96-well plate at a
density of 3.0 × 10
3 cells/well for proliferation assay.
Then for 5 days, every 24 h a batch of cells were stained
with 20 μl sterile MTT dye (5 mg/ml; Sigma, USA) at
37°C for 4 h, then culture medium was removed and
150 μl of DMSO was added and thoroughly mixed in
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measured by using a microplate reader. All experiments
were performed in triplicate.
Colony formation assay
Approximately 0.5 × 10
3 A549 cells transiently trans-
fected with dsP21-322, scramble dsRNA and mock were
plated in 100-mm culture dishes, respectively. After 18
days, cells were fixed with methanol and stained with
0.1% crystal violet. Visible colonies were manually
counted.
Flow cytometric analysis of apoptosis
An annexin V-fluorescein isothiocyanate apoptosis
detection kit (Zymed, USA) was used to detect cell
apoptosis. Approximately 1 × 10
6 A549 cells transiently
transfected with dsP21-322, scramble dsRNA and mock,
respectively, were harvested and analyzed by Flow Cyto-
metry (BD, USA).
In vitro chemosensitivity assay
The dsP21-322, scramble dsRNA and mock transfected
A549 cells were seeded in 96-well plate at a density of
5× 1 0
4 cells/well. The cells were then treated with
5 μg/ml cisplatin for 48 h.Then, 20 μlo fM T Ts t o c k
solution (5 mg/ml) was added to each well, and the cells
were incubated at 37°C for 4 h. The supernatant was
replaced with DMSO to dissolve formazan production.
T h eA 4 9 0n mv a l u e sw e r ea s s a y e di nam i c r o p l a t e
reader. The ratio of the absorbance of treated cells rela-
tive to that of the control cells was calculated and
expressed as a percentage of cell viability. The mean of
three parallel samples was calculated. Experiments were
performed in triplicate and standard deviations were cal-
culated based on the average of three experiments.
In vivo chemosensitivity assay
A549 cells (1 × 10
6) were injected subcutaneously into
t h er i g h tp o s t e r i o rl i m bo fB A L B / cn u d em i c e( 4 - 6
weeks old). When palpable tumors (about 100-130
mm
3) arose within 16-21 days, mice were randomized
to treatment and control groups. Three groups (five
mice each) received intratumoral injections of mixture
of 30 μg of LipofectamineTM2000-encapsulated dsP21-
322, scramble dsRNA and PBS respectively, every 3 days
for 3 weeks. The other two groups received intratumoral
injection of PBS combined with cisplatin or dsP21-322
combined with 5 mg/kg cisplatin, individually, every
3 days for 3 weeks. Tumor growth was monitored by
caliper-measuring two perpendicular tumor diameters
e v e r y3d a y s ,a n dt h ev o l u m eo ft h et u m o rw a sc a l c u -
lated from the formula: V = (width
2 × length × 0.5). At
the end of the experiment, tumor weight was assessed
by sacrificing the mice, and by removing and weighing
the tumor. Animal experiments in this study were car-
ried out in accordance with the medicine institutional
guidelines of Fourth Military Medical University.
Immunohistochemistry of tumors
The sections of the tumor tissues embedded in paraffin
were stained using mouse anti-p21 antibody (Santa
Cruz) at 1:50 dilution overnight at 4°C. After brief wash-
ing, all slides were stained and visualized with a Histo-
fine SAB-PO(M) kit (Nichirei, Tokyo, Japan) according
to the manufacturer’s instructions.
Statistical analysis
Results were expressed as Means ± standard deviation
(SD). Statistical analyses were performed using SPSS sta-
tistical software. Student’s t-test and one-way analysis of
variance (ANOVA) followed by Dunnett’s multiple com-
parison tests were adopted. Values of p < 0.05 were con-
sidered as significant and indicated by asterisks in the
figures.
Results
P21 was up-regulated by saRNA in A549 cell line
As an initial test of our study, we transfected saRNA
targeting the p21 gene promoter at position-322 relative
to the transcription start site (dsP21-322) into A549
cells for 72 h (Figure 1A). Semiquantitative RT-PCR and
Western blotting results showed that both mRNA and
protein expressions of p21 were elevated in dsP21-322
transfected A549 cells (Figure 1B, C), comparing with
mock or scramble dsRNA transfected group. To further
explore whether up-regulation of the p21 mRNA is
independent of p53 protein expression, we detected the
effect of dsP21-322 on p53 null Saos2 cells. As shown in
Figure 1D, dsP21-322 was able to elevate the p21
mRNA level in p53 null cells.
Lung carcinoma cell proliferation and colony formation
were inhibited by p21 up-regulation in vitro
An important characteristic of tumor cells is their
increased proliferative capability, which is often caused
by impaired regulation of the cell cycle. It has been
reported that p21 can regulate the cell cycle process by
binding and inhibiting cyclin-dependent kinases, so we
examined the effect of p21 transcriptional activation on
the proliferation of A549 cells in vitro. In this experi-
ment, cell proliferation was monitored by MTT assay
daily for 5 days. The cell growth curve showed that pro-
liferation of dsP21-322 transfected A549 cells was signif-
icantly inhibited in a time-dependent manner, while
scramble dsRNA transfected A549 cells showed no sig-
nificant inhibition of the proliferation (Figure 2A). Try-
pan blue exclusion results also showed that the cell
proliferation of dsP21-322 transfected A549 cells was
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expected from the results of MTT assay, the numbers of
colonies were obviously decreased in dsP21-322 trans-
fected A549 cells compared with mock and scramble
dsRNA transfected A549 cells (Figure 2C). Although up-
regulation of p21 could inhibit proliferation and colony
formation in A549 cells, there was no obviously differ-
ence in apoptotic rates between dsP21-322 transfected
cells and scramble dsRNA transfected cells detected by
Flow cytometric analysis (Figure 2D). All these results
s u g g e s t e dt h a tu p - r e g u l a t i o no fp 2 1g e n ee x p r e s s i o nb y
saRNA could lead to significant inhibition of lung carci-
noma cell proliferation in vitro.
The effect of up-regulation of p21 gene expression on
the cell cycle
It has been shown that overexpression of p21 results in
G1-, G2-, or S-phase arrest [14-16], we explored the cell
cycle changes in p21 up-regulated A549 cells. Cell cycle
analysis by flow cytometry method showed that the per-
centage of the cells in G1/G0 phase was increased in
dsP21-322 transfected cells (66.92%) compared with that
in the mock and scramble dsRNA transfected cells
(55.87% and 56.23% respectively) (Figure 3). Neverthe-
less, percentage of cells in S phase in dsP21-322 trans-
fected cells decreased to 25.67% compared with that in
mock and scramble dsRNA transfected cells (40.28%
and 40.15%, respectively). These results indicated that
up-regulation of p21 gene expression mainly blocked
A549 cells in G1/G0, which might lead to proliferation
inhibition of the cells.
The specific up-regulation of p21 gene expression
enhances cisplatin cytotoxicity in vitro
Previous study showed that p21-negative cells were
defective in nucleotide excision repair, which has been
suggested to increase sensitivity to certain chemothera-
peutic drugs [17]. So we next explored whether the
saRNA-mediated up-regulation of p21 gene expression
could affect the sensitivity of A549 cells to the anti-
tumor agent cisplatin. We treated the scramble dsRNA
or dsP21-322 transfected A549 cells by cisplatin with
concentrations ranging from 0.5 μg/ml to 10 μg/ml for
48 h. The relative cell viability at different cisplatin con-
centrations were made to calculate the IC50. The results
showed that the IC50 of dsP21-322 transfected cells was
decreased to 1.23 μg/ml compared with those of mock
and scramble dsRNA transfected groups (4.15 μg/ml
and 3.84 μg/ml respectively) (Figure 4A). To further
confirm the role of p21 in sensitivity of A549 cells to
cisplatin, the endogeneous p21 expression was knocked
down by p21-shRNA, the cytotoxicity of the cisplatin at
the concentration of 5 μg/ml was measured with MTT
assays. As shown in Figure 4B, the inhibition rates of
dsP21-322 treated cells increased statistically. While in
cells with p21 expression silenced by shRNA, the che-
mosensitivity of A549 cells to cisplatin was decreased
(p < 0.05).
Figure 1 dsP21-322 induces p21 gene expression in cell lines. (A) A schematic representation dsP21-322 position and sequence on the
promoter region of p21 gene. (B) Semiquantitative RT-PCR result showing elevated p21 mRNA expression in dsP21-322 transfected A549 cells.
(C) Western blot analysis showing increased p21 protein expression in dsP21-322 transfected A549 cells, and the results were normalized to b-
actin. (D) Semiquantitative RT-PCR result showing elevated p21 mRNA expression in dsP21-322 transfected Saos2 cells.
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Page 4 of 8Figure 2 Effects of dsP21-322 on cell proliferation, colony formation and apoptosis. (A) Mock, scramble dsRNA and dsP21-322 transiently
transfected cells were measured by MTT assay for the cell proliferation. (B) Mock, scramble dsRNA and dsP21-322 transfected A549 cells were
treated with cisplatin and numbers of viable cells were counted by Trypan blue exclusion. (C) The mock, scramble dsRNA and dsP21-322
transfected A549 cells were seeded onto 100-mm culture dishes at a concentration of 0.5 × 10
3 cells and cultured for 17 days. Colony formation
of dsP21-322 transfected A549 cells was inhibited obviously. (D) Apoptotic analysis by Flow Cytometry showing negative results in all of mock,
scramble dsRNA and dsP21-322 transfected A549 cells.
Figure 3 Cell cycle analysis of dsP21-322 transfected A549 cells by Flow Cytometry. It was shown that percentage of the cells in G1/G0
phase was increased in dsP21-322 transfected cell (66.92%) compared with that in the mock and scramble dsRNA transfected cells (55.87% and
56.23% respectively). Percentage of cells in S phase was decreased to 25.67% compared with that in the mock and scramble dsRNA transfected
cells (40.28% and 40.15%, respectively)
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cisplatin in vivo
In view of these findings in vitro, we further tested the
efficacy of dsP21-322 as an in vivo chemosensitivity
strategy in nude mouse xenograft model. When palpable
tumors arose in the right flank of mice, the mice
received PBS, scramble dsRNA, dsP21-322, PBS com-
bined with cisplatin or dsP21-322 combined with cispla-
tin intratumorally every 3 days until the end of the
experiment. The tumor size was monitored every 3 days
for three weeks. As shown in Figure 5A,B, cisplatin
treatment combining with dsP21-322 inhibited the
xenograft tumor growth significantly compared with the
group treated with cisplatin combining with PBS (p <
0.05). In addition, we detected the expression of p21 in
the formalin embedded tumor tissue using anti-p21
antibody. As shown in Figure 5C, the expression of p21
proteins were increased in dsP21-322 treated tumor tis-
sues. Hence, p21 saRNA along with chemotherapeutic
cisplatin could produce a synergistic cytotoxicity effect
on the cell proliferation of lung carcinoma in vivo.
Discussion
Lung cancer is considered usually to acquire resistance
to chemotherapy during multiple courses of therapy,
which leads to poor prognosis, compared with other
types of human malignancies. Thus, attempts at improv-
ing the survival of patients affected by this disease
depend largely on strategies targeting development of
tumor cell resistance to chemotherapy drugs, which can-
not be rationally planned without a detailed knowledge
of the mechanisms underlying this phenomenon.
Searching for molecular targets participating in the pro-
cess of drug-resistance and utilizing these targets to
oppose drug-resistance in chemotherapy will be benefi-
cial to the clinical therapy. There is evidence that altera-
tion of CDK inhibitors in cancer may affect the
response to chemotherapeutic treatment. Loss expres-
sion of p21 has been linked to drug-resistance in many
in vitro cellular models. However, to date, evidence
about the relationship between this CDK inhibitor and
lung carcinoma drug-resistance has been lacking.
It has been reported that genetic and epigenetic
abnormalities can induce lower expression of p21, which
is linked to chemoresistance in many in vitro cellular
models [18]. Colon cancer cells with deletions of
p21WAF1/CIP1 showed abnormal response to treat-
ment with doxorubicin, which is due to abnormal block
to G2 decreases undergoing mitosis of cell [19]. It was
also demonstrated that forced overexpression of
p21WAF1/CIP1 in osteosarcoma cells increased sensitiv-
ity to chemotherapeutic agents and leaded to G1 and
G2/M arrest [20,21]. These results indicate that deletion
or lower expression of p21 is involved in drug-resis-
tance. Various mechanisms exist to regulate the levels of
p21 in a cell including transcriptional regulation, epige-
netic silencing, mRNA stability, and ubiquitin-dependent
and-independent degradation of the protein [22]. The
dsRNA used in RNAa study was designed by closely
following rational siRNA design rules and avoided
CpG-rich islands. These characteristics may direct the
modification of histone and further the activation or
silencing of target gene [11]. Cisplatin have been used as
first-line therapy to treat lung carcinoma, but its cura-
tive effect is far from satisfactory. Thus, in order to
improve the prognosis of patients with type of refractory
cancer, it is necessary to identify and target genes which
conduce to the treatment of lung carcinoma, such as
enhancement of conventional chemotherapy.
In this study, we elevated the expression of p21 in
lung carcinoma A549 cells by using saRNA targeting the
promoter region of p21, which has been demonstrated
to transcriptionally activate the expression of p21 gene.
We detected up-regulation of p21 after tranfection of
Figure 4 Toxicity assay of cisplatin on dsP21-322 transfected A549 cells. (A) Human lung cancer A549 cells transfected with mock,
scramble dsRNA or dsP21-322 was treated by cisplatin with concentrations ranging from 0.5 μg/ml to 10 μg/ml for 48 h. The IC50 of dsP21-322
treated cells was decreased to 1.23 μg/ml compared with those of mock and scramble dsRNA transfected groups (4.15 μg/ml and 3.84 μg/ml
respectively). (B) Transiently transfected A549 cells were treated with 5 μg/ml cisplatin, drug sensitivity analysis was performed with MTT assays.
Data represent the mean + SE of three independent experiments. * p < 0.05.
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the results showed that the expression of p21 could be
increased in lung cancer cells by saRNA transfection.
To explore the phenotype changes induced by p21 up-
regulation in A549 cells, we detected the proliferation,
colony formation, apoptosis and cell cycle change of
saRNA transfected cells. The results showed that up-reg-
ulation of p21 by transcriptional activation inhibited the
proliferation and colony formation of lung cancer cells.
Cell cycle analysis showed that endogenous p21 up-regu-
lation induced cell accumulation both in the G1/G0
phase in lung cancer cells, which leads to proliferation
inhibition of lung cancer cells, but there was no apoptosis
cells detected after dsP21-322 transfection. It was
reported that p21 plays dual roles as both as pro and
anti-apoptotic gene. Whether p21 exhibits pro or anti-
apoptotic effects is likely to depend on the specific cellu-
lar context [23]. In our study, we did not detect obviously
difference in apoptotic rates between dsP21-322 trans-
fected cells and scramble dsRNA transfected cells. These
data indicated that activation of p21 expression inhibited
the proliferation and enhanced chemosensitivity to
cisplatin by process unrelated with apoptotic pathway.
Then, we detected the chemosensitivity of saRNA trans-
fected A549 cells to cisplatin in vitro, the results showed
that up-regulation of p21 obviously enhanced the sensi-
tivity of A549 cells to cisplatin in vitro. Although we did
not find the precise mechanism of this phenomenon,
further studies are needed to clarify the accrual role of
p21 up-regulation to chemosensitivity of cisplatin. We
observed that chemosensitivity of dsP21-322 transfected
A549 cells to paclitaxel also increased comparing with
control group. Chemotherapy with combination of plati-
num drug and paclitaxel is a relative effective strategy in
non-small-cell lung carcinomas therapy. Enhancement of
chemosensitivity to both cisplatin and paclitaxel (Addi-
tional file 1, Figure S1) indicates that it is due to their
crossing in the signal pathways for the chemotherapeutic
effect. Since the up-regulation of p21 gene expression
exerts profound effects on cell growth and enhances che-
mosensitivity to cisplatin, we explored the therapeutic
role of p21 in combination with cisplatin in animal mod-
els. We observed that tumor growth was inhibited more
obviously in the group treated with dsP21-322 combining
Figure 5 Up-regulation of p21 gene expression enhanced cisplatin cytotoxicity in vivo. (A and B) Aliquots of 1.0 × 10
6 A549 cells were
suspended in 1:1 PBS subcutaneously inoculated into the right flank of each mouse. When palpable tumors were observed, mice were
stochastically assigned to 5 groups (n = 5). Mice were received PBS, scramble dsRNA, dsP21-322, cisplatin, or mixture of dsP21-322 and cisplatin
intratumorally every 3 days for three weeks. During three weeks treatment, tumor volume was monitored and tumor growth was curved. (C)
Expressions of p21 in tumor tissues treated with dsP21-322 were assessed by immunohistochemical staining.
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dsRNA with cisplatin. In this study, as reported on other
human malignancies, results from chemosensitivity tests
showed that the RNAa-mediated up-regulation of p21
gene expression synergistically enhanced the cytotoxicity
o fc i s p l a t i nb o t hi nv i t r oa n di nv i v o ,w h i c hm a d eu s
believe that cisplatin chemotherapy could be more effec-
tive in combination with RNAa-mediated up-regulation
of p21 gene expression.
Conclusion
In summary, this study demonstrates that up-regulating
expression of p21 in lung cancer by RNAa technique
can inhibit proliferation, enhance chemotherapeutic sen-
sitivity to cisplatin in vitro and vivo, which may signifi-
cantly contribute to therapy of lung cancer, especially
for drug-resistance tumor therapy.
Additional material
Additional file 1: Toxicity assay of paclitaxel on dsP21-322
transfected A549 cells. The IC50 of dsP21-322 treated cells was
decreased to 0.17 μg/ml compared with mock or scramble dsRNA
transfected group (0.29 μg/ml and 0.30 μg/ml respectively)
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